UCB SA is a global biopharmaceutical company founded in 1928 that researches, develops, and delivers medicines for severe neurological and autoimmune diseases. The company operates in neurology and immunology, focusing on conditions such as epilepsy, myasthenia gravis, psoriasis, hidradenitis suppurativa, and osteoporosis. Its portfolio includes the IL-17A/F inhibitor bimzelx (bimekizumab) and treatments for rare epilepsy syndromes acquired through the purchase of Zogenix. UCB also holds a licensing agreement with Antengene and has acquired companies including IMIDomics, Neurona Therapeutics, Candid Therapeutics, Engage Therapeutics, Ra Pharma, Handl Therapeutics, Celltech, and Schwarz Pharma. The company serves patients and healthcare professionals globally, offering the UCBCares patient support program and collaborating with partners such as Microsoft for drug discovery.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Drug Manufacturers - Specialty & Generic Homepage ucb.com
Sector Healthcare IR page ucb.com/investors
Tags
biotechnology, neurology, immunology, rare diseases, patient support, drug discovery, UCB, bimzelx, bimekizumab, UCBCares, IMIDomics, Neurona Therapeutics, Candid Therapeutics, Antengene, Zogenix, Engage Therapeutics, Ra Pharma, Handl Therapeutics, Celltech, Schwarz Pharma, Microsoft
Press page ucb.com/newsroom/press-releases

Metrics

Valuation  
Market cap € 55.454B
Market cap (USD) $ 60.822B
P/E 52.07
PEG 236.62
P/BV 5.40
P/S 9.01
P/OCF 44.65
P/FCF 60.28
Dividend yield —
Turnover / mcap —
Returns  
ROE 11.2%
ROI 9.4%
ROIC 7.0%
Profit margin 17.3%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) 0.22%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 76
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2024 FY 2023 FY 2022 FY 2021
Revenue 6.152B 5.252B 5.517B 5.777B
Net profit 1.065B 343M 418M 1.058B
Free cash flow 920M 445M 748M 1.06B

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

  • Continued strong performance supports higher 2026 expectations, with revenue growth anticipated in the low twenties at constant exchange rates, up from low- to mid-teens
  • Higher revenue growth is driving significant operating leverage, with adjusted EBITDA growth expected in the low- to mid-forties at constant exchange rates, up from mid-teens to low-twenties
  • Upgrade is driven by BIMZELX® stronger performance in the U.S., reflecting robust patient demand and favorable net pricing dynamics, alongside CIMZIA® solid contribution reflecting continued volume growth and more favorable pricing 

Brussels (Belgium), 22 October 2026 – 07:00 (CET) – Regulated information - Inside Information – UCB today announced a further upgrade to its 2026 financial guidance, reflecting sustained business momentum and further progress against its long-term growth ambitions.

BIMZELX® performance continues to strengthen based on robust volume growth across indications, faster patient conversion and higher retention rates. This is the result of focused investment, expanding access, a differentiated clinical profile and compelling BE BOLD data, which together are driving patient demand and market share gains. More favorable net pricing as a result of a more favorable channel mix is further strengthening performance and value per patient. CIMZIA® also continues to deliver volume growth across markets despite a contracting anti-TNF market, while 340B dynamics have been more moderate, supported by optimized claims diligence and the impact of recent Orphan Drug Designation.

Higher revenue growth is expected to drive greater operating leverage and significant margin expansion.

Sandrine Dufour, CFO of UCB says: “The continued strong performance of BIMZELX® and CIMZIA® demonstrates the strength of our differentiated innovation strategy and our ability to translate innovation into sustainable growth. At the same time, excellence in execution is enabling us to convert robust revenue growth into greater operating leverage and profitability while continuing to invest in our future. This gives us confidence not only to raise our 2026 expectations but also in our ability to deliver meaningful impact for the those we serve."

The upgraded financial guidance excludes proceeds from the sale of a Priority Review Voucher (PRV), representing an additional low- to mid-single-digit percentage points uplift to revenue and adjusted EBITDA, respectively. 

UCB will publish the Full Year 2026 results and formal financial guidance for 2027 on February 25, 2027.

Transparency notification Wellington Bull 0 Bear 0 Routine

Brussels (Belgium), 19 October 2026 – 22:00 (CET) – Regulated information 

1.  Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from Wellington Management Group LLP (having its registered offices at 280 Congress Street, Boston, MA 02210, USA) on 15 October 2026. 

Wellington Management Group LLP has notified that, following a disposal of UCB voting securities or voting rights by its affiliates, its shareholding in UCB SA/NV has decreased and it has crossed the 3% threshold downwards, on 14 October 2026.

On 14 October 2026, Wellington Management Group LLP (taking into account the holdings of its affiliates) owned less than 3% of UCB shares with voting rights or equivalent financial instruments of the total number of shares issued by the company (194 505 658), versus 3.01% (5 846 454 voting rights) in the previous notification dated 26 August 2026.

2.  Content of the notification

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights; downward crossing of the lowest threshold. 
  • Notification by: A parent undertaking or a controlling person.
  • Persons subject to the notification requirement: 

ae8f77aa082b2c64_800x800ar.png

  • Date on which the threshold is crossed: 14 October 2026. 
  • Threshold crossed (in %): 3%.
  • Denominator: 194 505 658.
  • Notified details:

beca0b139bd3816e_800x800ar.png

  • Chain of controlled undertakings through which the holding is effectively held:

Wellington Management Company LLP is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Management Group LLP. Wellington Management Hong Kong Ltd, Wellington Management International Ltd and Wellington Management Europe GmbH are direct controlled undertakings of Wellington Management Global Holdings, Ltd. which, in turn, is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.  The shares are registered in the names of the Accounts or nominees according to their respective holdings.

  • Additional information: Wellington Management Company LLP, Wellington Management Hong Kong Ltd, Wellington Management International Ltd and Wellington Management Europe GmbH are investment management companies and can exercise the voting rights at their discretion in the absence of specific instructions from the beneficial owners of the shares.

3.  Further information 

This press release and the detailed transparency notification are available on UCB SA/NV’s website via the following link .
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link .

  • ZILBRYSQ is the first and only macrocyclic peptide C5 inhibitor approved as a self-administered once-daily, subcutaneous autoinjector for adults living with generalized myasthenia gravis (gMG) in the U.S.¹
  • ZILBRYSQ now offers two self-administration options for adults living with gMG who are anti-acetylcholine receptor (AChR) antibody positive.1,2
  • The autoinjector is designed to help simplify self-administration of ZILBRYSQ, offering patients another administration option and a more convenient treatment experience.3,4
  • Approval is supported by data showing ZILBRYSQ bioequivalence between the autoinjector and the existing prefilled syringe, with complete dose delivery achieved for 99.8% (n=449*) of autoinjector administrations. Patients reported high satisfaction with self-injection of ZILBRYSQ using the autoinjector device.3

Brussels, Belgium and Atlanta, Georgia – October 16, 2026 - 7:00 CET – UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the first self-administered once-daily, autoinjector administration option for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive with ZILBRYSQ® (zilucoplan).¹ The autoinjector is designed to help simplify self-administration of ZILBRYSQ, offering patients an another administration option and a more convenient treatment experience.3,4

“This approval is the answer to a question on which we’ve been relentlessly focused: how do we continue to improve an already effective therapy for use every single day?” said Kimberly Moran, PhD, SVP & Head, U.S. Rare Diseases at UCB. “As the first treatment to be approved as a once-daily autoinjector option for adults living with gMG in the U.S., ZILBRYSQ now provides the same therapy via another administration option. At UCB, we are committed to science and make it our point to continually help improve how people experience it.”

The ZILBRYSQ autoinjector is designed to automatically deliver a pre-defined dose when activated against the skin.1,3 Prior to the autoinjector’s approval, ZILBRYSQ was available as a self-administered prefilled syringe (PFS). Patients or their care partners will now have another portable treatment solution. 

“For a chronic condition like gMG, having different administration options allows patients to choose the approach that best fits their individual preferences and routines,” said Donatello Crocetta, Global Head of Medical Affairs and Chief Medical Officer at UCB. “From a medical standpoint, it was essential to confirm that this added administrative option didn’t come at the expense of safety and efficacy. The data supporting the autoinjector’s complete dose delivery show that this option continues to offer effective treatment for patients.” 

The approval of the ZILBRYSQ autoinjector for self-administration is supported by data from the following studies: 

  • DV0012 – a Phase 1, open-label, single-center, two-period crossover study in healthy adult volunteers (n=14) which established bioequivalence of ZILBRYSQ delivered via an autoinjector compared with a PFS.3
  • DV0013 – a Phase 3b open-label, multi-center study in adult patients (n=31) with gMG self-administering ZILBRYSQ via autoinjector once daily. Complete dose delivery was achieved for 99.8% (n=449*) of autoinjector administrations. Patients reported high satisfaction with self-injection of ZILBRYSQ using the autoinjector device.3 Self-administration was generally well tolerated. The most common TEAE was injection-site pain (n=3; 9.7%).3
  • A human factors validation study of 100 participants† demonstrating that 90% successfully completed an injection with the ZILBRYSQ autoinjector on their first attempt without training.5

UCB expects the autoinjector to be available commercially in Q1 2027.

*Total autoinjectors used and returned.

†Participants defined as patients with gMG or those exhibiting ocular symptoms (injection-experienced and injection-naïve); caregivers (injection-experienced and injection-naïve); and healthcare professionals (HCPs).

About ZILBRYSQ® (zilucoplan)
ZILBRYSQ (a synthetic macrocyclic peptide) is a once-daily, self-administered, subcutaneous injection that works by blocking complement component 5 (C5), a protein involved in the immune-mediated damage that occurs at the neuromuscular junction in gMG.1,6 ZILBRYSQ is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.¹

The precise mechanism through which ZILBRYSQ exerts therapeutic effects in gMG is unknown.

In addition to ZILBRYSQ, UCB’s gMG portfolio includes RYSTIGGO® (rozanolixizumab-noli), a subcutaneously infused monoclonal antibody targeting the neonatal Fc receptor (FcRn) approved by the FDA for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.7 With two approved medicines with distinct mechanisms of action, UCB continues to offer physicians and the U.S. gMG community a choice of targeted therapies from a single company.

The precise mechanism through which RYSTIGGO exerts therapeutic effects in gMG is unknown.

About generalized myasthenia gravis (gMG)

gMG is a rare neuromuscular autoimmune disease that has a global prevalence of 150–350 cases per 1 million people.8 People living with gMG can experience a variety of symptoms, including severe muscle weakness that can result in double vision, drooping eyelids, difficulty with swallowing, chewing and talking, as well as life-threatening weakness of the muscles of respiration.9,10

In gMG, pathogenic autoantibodies can impair synaptic transmission at the neuromuscular junction (NMJ) by targeting specific proteins on the post-synaptic membrane.11 This disrupts the ability of the nerves to stimulate the skeletal muscle and results in a weaker contraction.11 gMG can occur in any race, gender or age.9,10,12

ZILBRYSQ®▼ (zilucoplan) EU/EEA** Important Safety Information2

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new
safety information. Healthcare professionals are asked to report any suspected adverse reactions.

The most frequently reported adverse reactions were injection site reactions (injection site bruising (13.9%) and injection site pain (7.0%)) and upper respiratory tract infections (nasopharyngitis (5.2%), upper respiratory tract infection (3.5%) and sinusitis (3.5%)). The adverse reactions from the pooled placebo controlled (n=115) and open-label extension (n=213) studies in gMG are as follows: Very common adverse reactions: (≥ 1/10): Upper respiratory tract infections and Injection site reactions; Common adverse reactions (≥ 1/100 to < 1/10): Diarrhea, Lipase increased, Amylase increased and Morphea; Uncommon adverse reaction (≥ 1/1000 to < 1/100) blood eosinophils increased. Zilucoplan is contra-indicated in patients with hypersensitivity to the active substance or to any of the excipients, in patients who are not currently vaccinated against Neisseria meningitidis and in patients with unresolved Neisseria meningitidis infection. Due to its mechanism of action, the use of zilucoplan may increase the patient’s susceptibility to infections with Neisseria meningitidis. As a precautionary measure, all patients must be vaccinated against meningococcal infections, at least 2 weeks prior to the start of treatment. If treatment needs to start less than 2 weeks after vaccination against meningococcal infections, the patient must receive appropriate prophylactic antibiotic treatment until 2 weeks after the first vaccination dose. Meningococcal vaccines reduce but do not completely eliminate the risk of meningococcal infections. Vaccines against serogroups A, C, Y, W, and where available, serogroup B, are recommended for preventing the commonly pathogenic meningococcal serogroups. Vaccination and prophylactic antibiotic treatment should occur according to most current relevant guidelines. During treatment, patients should be monitored for signs and symptoms of meningococcal infection and evaluated immediately if infection is suspected. In case of a suspected meningococcal infection, appropriate measures such as treatment with antibiotics and discontinuation of treatment, should be taken until the meningococcal infection can be ruled out. Patients should be instructed to seek immediate medical advice if signs or symptoms of meningococcal infections occur. Prescribers should be familiar with the educational materials for the management of meningococcal infections and provide a patient card and patient/carer guide to patients treated with zilucoplan. In addition to Neisseria meningitidis, patients treated with zilucoplan may also be susceptible to infections with other Neisseria species, such as gonococcal infections. Patients should be informed on the importance of gonorrhea prevention and treatment. Prior to initiating zilucoplan therapy, it is recommended that patients initiate immunizations according to current immunization guidelines. 

Please consult the full prescribing information in relation to other side effects, full safety and prescribing information. Zilbrysq, INN-zilucoplan (europa.eu) Date of last revision: 09 July 2026.

*EU/EEA means European Union/European Economic Area.

Important Safety Information about ZILBRYSQ® (zilucoplan) in the U.S.1

ZILBRYSQ is a complement inhibitor indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS 
Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early. ZILBRYSQ, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis.

  • Complete or update meningococcal vaccination (for serogroups A, C, W, and Y, and B) at least 2 weeks prior to the first dose of ZILBRYSQ, unless the risk of delaying therapy outweigh the risks of developing a meningococcal infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccination against meningococcal bacteria in patients receiving a complement inhibitor.
  • Persons receiving ZILBRYSQ are at increased risk for invasive disease caused by Neisseria meningitidis, even if they develop antibodies following vaccination. Monitor patients for signs of serious meningococcal infections and evaluate immediately if infection is suspected.

Because of the risk of serious meningococcal infections, ZILBRYSQ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ZILBRYSQ REMS. 

CONTRAINDICATIONS 

ZILBRYSQ is contraindicated for initiation in patients with unresolved Neisseria meningitidis infection. 

WARNINGS AND PRECAUTIONS 
Serious Meningococcal Infections
 
ZILBRYSQ, a complement inhibitor, increases a patient’s susceptibility to serious, life-threatening, or fatal infections caused by meningococcal bacteria (septicemia and/or meningitis) in any serogroup, including non-groupable strains. Life-threatening and fatal meningococcal infections have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. The initiation of ZILBRYSQ treatment is contraindicated in patients with unresolved serious Neisseria meningitidis infection. Complete or update meningococcal vaccination (for serogroups A, C, W, Y and B) at least 2 weeks prior to administering the first dose of ZILBRYSQ, according to current ACIP recommendations for patients receiving a complement inhibitor. If urgent ZILBRYSQ therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer meningococcal vaccines as soon as possible. Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if infection is suspected. Consider interruption of ZILBRYSQ in patients who are undergoing treatment for serious meningococcal infection, depending on the risks of interrupting treatment in the disease being treated.

ZILBRYSQ REMS 

Due to the risk of meningococcal infections, ZILBRYSQ is available only through a restricted program under a REMS called ZILBRYSQ REMS. Under the ZILBRYSQ REMS, prescribers must enroll in the program. Prescribers must counsel patients about the risk of meningococcal infection, provide the patients with the REMS educational materials, and ensure patients are vaccinated with meningococcal vaccines. Additional information on the REMS requirements is available at www.ZILBRYSQREMS.com or 1-877-414-8353.

Other Infections 

Serious infections with Neisseria species (other than Neisseria meningitidis), including disseminated gonococcal infections, have been reported in patients treated with complement inhibitors. ZILBRYSQ blocks terminal complement activation; therefore, patients may have increased susceptibility to infections, especially with encapsulated bacteria, such as infections caused by Neisseria meningitidis but also Streptococcus pneumoniae, Haemophilus influenzae, and to a lesser extent, Neisseria gonorrhoeae. Administer vaccinations for the prevention of Streptococcus pneumoniae infection according to ACIP recommendations. Patients receiving ZILBRYSQ are at increased risk for infections due to these organisms, even if they develop antibodies following vaccination.

Pancreatitis And Other Pancreatic Conditions 

Pancreatitis and pancreatic cysts have been reported in patients treated with ZILBRYSQ. Patients should be informed of this risk before starting ZILBRYSQ. Obtain lipase and amylase levels at baseline before starting treatment with ZILBRYSQ. Discontinue ZILBRYSQ in patients with suspected pancreatitis and initiate appropriate management until pancreatitis is ruled out or has resolved. 

ADVERSE REACTIONS 

In a placebo-controlled study, the most common adverse reactions (reported in at least 10% of gMG patients treated with ZILBRYSQ) were injection site reactions, upper respiratory tract infections, and diarrhea. 

Please see the full Prescribing Information for additional Important Safety Information.

RYSTIGGO®▼ (rozanolixizumab) EU/EEA* Abbreviated Product Information13

▼This medicinal product is subject to additional monitoring. This will allow quick
identification of new safety information. Healthcare professionals are asked to report any
suspected adverse reactions.

Rystiggo 140 mg/ml solution for injection. Each ml of solution for injection contains 140 mg
of rozanolixizumab. One vial of 2 ml contains 280 mg of rozanolixizumab. One vial of 3 ml
contains 420 mg of rozanolixizumab. One vial of 4 ml contains 560 mg of rozanolixizumab.
One vial of 6 ml contains 840 mg of rozanolixizumab.

Rozanolixizumab is a recombinant, humanised anti-neonatal Fc receptor (FcRn)
immunoglobulin G 4P (IgG4P) monoclonal antibody produced in Chinese Hamster Ovary
(CHO) by recombinant DNA technology.

Therapeutic indications: Rystiggo is indicated as an add-on to standard therapy for the
treatment of generalised myasthenia gravis (gMG) in adult patients who are antiacetylcholine
receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody
positive.

Posology and method of administration: Rystiggo should be initiated and supervised
by specialist healthcare professionals experienced in the management of patients with
neuromuscular or neuro-inflammatory disorders. A treatment cycle consists of 1 dose per
week for 6 weeks. The recommended total weekly dose, should be given according to the
patient’s body weight as follows : 280 mg (body weight ≥35 to <50 kg), 420 mg (body
weight ≥50 to <70 kg), 560 mg (body weight ≥70 to <100 kg), 840 mg (body weight
≥100 kg). For subcutaneous infusion using a pump. Subsequent treatment cycles should be
administered according to clinical evaluation.

Contraindications: Hypersensitivity to the active substance(s) or to any of the excipients.

Special warnings and precautions for use:

Myasthenic crisis

Treatment with rozanolixizumab in patients with impending or manifest myasthenic crisis
has not been studied. The sequence of therapy initiation between established therapies for
MG crisis and rozanolixizumab, and their potential interactions, should be considered.

Aseptic meningitis

Aseptic meningitis (drug induced aseptic meningitis) has been reported following
rozanolixizumab treatment. If symptoms consistent with aseptic meningitis (headache,
pyrexia, neck stiffness, nausea, vomiting) occur, diagnostic workup and treatment should be
initiated as per standard of care.

Infections

As rozanolixizumab causes transient reduction in IgG levels the risk of infections may
increase. Treatment with rozanolixizumab should not be initiated in patients with a clinically
important active infection until the infection resolves or is adequately treated. During
treatment with rozanolixizumab, clinical signs and symptoms of infections should be
monitored. If a clinically important active infection occurs, withholding rozanolixizumab until
the infection has resolved should be considered.

Hypersensitivity

Infusion reactions such as rash or angioedema may occur. In the clinical trial, these were
mild to moderate. Patients should be monitored during treatment with rozanolixizumab and
for 15 minutes after the administration is complete for clinical signs and symptoms of
hypersensitivity reactions. If a hypersensitivity reaction occurs during administration,
rozanolixizumab infusion should be discontinued and appropriate measures should be
initiated if needed. Once resolved, administration may be resumed.

Vaccination

Immunisation with vaccines during rozanolixizumab therapy has not been studied. The
safety of immunisation with live or live-attenuated vaccines and the response to
immunisation with vaccines are unknown. All vaccines should be administered according to
immunisation guidelines and at least 4 weeks before initiation of treatment. For patients that
are on treatment, vaccination with live or live-attenuated vaccines is not recommended. For
all other vaccines, they should take place at least 2 weeks after the last infusion of a
treatment cycle and 4 weeks before initiating the next cycle.

Excipients

This medicinal product contains 29 mg of proline in each ml. The use in patients suffering
from hyperprolinaemia should be restricted to cases where no alternative treatment is
available.

Undesirable effects: The most commonly reported adverse reactions were headache
(48.4%), diarrhoea (25.0%) and pyrexia (12.5%). The adverse reactions from the placebocontrolled
study in gMG were as follows: Very common (≥1/10) headache, diarrhoea, and
pyrexia; Common (≥1/100 to <1/10) rash, angioedema, arthralgia, and injection site
reactions; Not known, aseptic meningitis (from spontaneous post-marketing reporting).
Description of selected adverse reactions : In MG0003, headache was the most common
reaction reported in 31 (48.4%) and 13 (19.4%) of the patients treated with
rozanolixizumab and placebo, respectively. All headaches, except 1 (1.6%) severe
headache, were either mild (28.1% [n=18]) or moderate (18.8% [n=12]) and there was no
increase in incidences of headache with repeated cyclic treatment.

Please refer to local labelling in relation to other side effects. Healthcare professionals are
asked to report any suspected adverse reactions via the national reporting system.

The date of last revision of the European Product Information: 18th July 2024. Please refer
to the full Prescribing information in your country before prescribing. Supply classification:
Medical product subject to medical prescription. EUCC code: EU/1/23/178

https://www.ema.europa.eu/

*EU is an abbreviation for the European Union. EEA is an abbreviation for the European
Economic Area.

Important Safety Information about RYSTIGGO® (rozanolixizumab-noli) in the US7

RYSTIGGO (rozanolixizumab-noli) is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.13 

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS 
Infections: RYSTIGGO may increase the risk of infection. Delay RYSTIGGO administration in patients with an active infection until the infection is resolved. During treatment with RYSTIGGO, monitor for clinical signs and symptoms of infection. If serious infection occurs, administer appropriate treatment and consider withholding RYSTIGGO until the infection has resolved.

Immunization
Immunization with vaccines during RYSTIGGO treatment has not been studied. The safety of immunization with live or live-attenuated vaccines and the response to immunization with any vaccine are unknown. Because RYSTIGGO causes a reduction in IgG levels, vaccination with live-attenuated or live vaccines is not recommended during treatment with RYSTIGGO. Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with RYSTIGGO.

Aseptic Meningitis: Serious adverse reactions of aseptic meningitis (also called drug-induced aseptic meningitis) have been reported in patients treated with RYSTIGGO. If symptoms consistent with aseptic meningitis develop, diagnostic workup and treatment should be initiated according to the standard of care.

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema and rash, were observed in patients treated with RYSTIGGO. Management of hypersensitivity reactions depends on the type and severity of the reaction. Monitor patients during treatment with RYSTIGGO and for 15 minutes after for clinical signs and symptoms of hypersensitivity reactions. If a reaction occurs, institute appropriate measures if needed.

ADVERSE REACTIONS
In a placebo-controlled study, the most common adverse reactions (reported in at least 10% of RYSTIGGO-treated patients) were headache, infections, diarrhea, pyrexia, hypersensitivity reactions, and nausea. Serious infections were reported in 4% of patients treated with RYSTIGGO. Three fatal cases of pneumonia were identified, caused by COVID-19 infection in two patients and an unknown pathogen in one patient. Six cases of infections led to discontinuation of RYSTIGGO.

Please refer to the full Prescribing Information for additional Important Safety Information.

Prompts

UCB SA (ticker UCB), listed in Belgium.

ETFs Holding UCB SA

ETF Weight in ETF Shares Market value As of
BCIL 5.32% 14,295 $ 4.67M Nov 12, 2026
FMED 1.60% 3,300 $ 825.27K Aug 31, 2026
FFDI 0.63% 477 $ 122.607K Jul 31, 2026
RCGE 0.62% 1,953 $ 620K Nov 18, 2026
FFGX 0.43% 920 $ 236.474K Jul 31, 2026
DIHP 0.43% 86,983 $ 28.416M Nov 12, 2026
FFLG 0.39% 9,047 $ 2.325M Jul 31, 2026
DFSI 0.33% 12,017 $ 3.926M Nov 12, 2026
QUIZ 0.28% 1,044 $ 261.152K Aug 31, 2026
UMMA 0.27% 3,188 $ 797.296K Aug 31, 2026
SEIE 0.25% 9,681 $ 2.9M Jun 30, 2026
DXIV 0.25% 1,838 $ 600.442K Nov 12, 2026
FFLC 0.22% 10,387 $ 2.67M Jul 31, 2026
DFAI 0.18% 100,801 $ 32.93M Nov 12, 2026
AVDE 0.17% 104,330 $ 33.635M Nov 16, 2026
AVIV 0.16% 10,546 $ 3.4M Nov 16, 2026
AVSD 0.16% 1,798 $ 579.651K Nov 16, 2026
TOUS 0.16% 9,735 $ 2.499M Jul 31, 2026
NTSI 0.15% 2,546 $ 762.641K Jun 30, 2026
TIER 0.14% 188 $ 48.256K Jul 31, 2026
DFIC 0.13% 63,338 $ 20.691M Nov 12, 2026
RINT 0.13% 613 $ 183.508K Jun 30, 2026
JSTC 0.11% 968 $ 314.392K Nov 17, 2026
IVSI 0.10% 27 $ 8,082.72 Jun 30, 2026
DFAX 0.09% 33,573 $ 10.968M Nov 12, 2026
IQSZ 0.05% 365 $ 93.478K Jul 31, 2026